You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 19, 2024

VIIBRYD Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Viibryd patents expire, and when can generic versions of Viibryd launch?

Viibryd is a drug marketed by Abbvie and is included in one NDA.

The generic ingredient in VIIBRYD is vilazodone hydrochloride. There are fourteen drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the vilazodone hydrochloride profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Viibryd

A generic version of VIIBRYD was approved as vilazodone hydrochloride by TEVA PHARMS USA on September 30th, 2019.

  Try a Trial

Drug patent expirations by year for VIIBRYD
Drug Prices for VIIBRYD

See drug prices for VIIBRYD

Drug Sales Revenue Trends for VIIBRYD

See drug sales revenues for VIIBRYD

Recent Clinical Trials for VIIBRYD

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Forest LaboratoriesPhase 1
New York State Psychiatric InstitutePhase 4
Forest LaboratoriesPhase 3

See all VIIBRYD clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for VIIBRYD
Paragraph IV (Patent) Challenges for VIIBRYD
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
VIIBRYD Tablets vilazodone hydrochloride 10 mg, 20 mg, and 40 mg 022567 5 2015-01-21

US Patents and Regulatory Information for VIIBRYD

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie VIIBRYD vilazodone hydrochloride TABLET;ORAL 022567-001 Jan 21, 2011 AB RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Abbvie VIIBRYD vilazodone hydrochloride TABLET;ORAL 022567-002 Jan 21, 2011 AB RX Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Abbvie VIIBRYD vilazodone hydrochloride TABLET;ORAL 022567-003 Jan 21, 2011 AB RX Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for VIIBRYD

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie VIIBRYD vilazodone hydrochloride TABLET;ORAL 022567-001 Jan 21, 2011 ⤷  Try a Trial ⤷  Try a Trial
Abbvie VIIBRYD vilazodone hydrochloride TABLET;ORAL 022567-002 Jan 21, 2011 ⤷  Try a Trial ⤷  Try a Trial
Abbvie VIIBRYD vilazodone hydrochloride TABLET;ORAL 022567-003 Jan 21, 2011 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for VIIBRYD

See the table below for patents covering VIIBRYD around the world.

Country Patent Number Title Estimated Expiration
Cyprus 1109447 ⤷  Try a Trial
Portugal 1397357 ⤷  Try a Trial
Slovakia 288162 ⤷  Try a Trial
Canada 2451028 FORMES POLYMORPHES DE CHLORHYDRATE DE 1-¬4-(5-CYANOINDOL-3-YL)BUTYL|-4-(2-CARBAMOYLBENZOFURAN-5-YL)PIPERAZI NE (POLYMORPHIC FORMS OF 1-[4-(5-CYANOINDOL-3-YL)BUTYL]-4-(2-CARBAMOYLBENZOFURAN-5-YL) PIPERAZINE HYDROCHLORIDE) ⤷  Try a Trial
Japan 5411734 ⤷  Try a Trial
Poland 178137 ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.